The FDA has cleared their once-weekly Factor VIII replacement therapy Altuviiio (efanesoctocog alfa) for adults and children with haemophilia A, giving Sanofi and Sobi a successor to well ...

The CHMP also recommended for approval Takeda's Altuviiio (efanesoctocog alfa) as a once-weekly treatment for hemophilia A. Altuviiio, which was developed with Swedish pharma Sobi, is approved in ...

Sanofi expects to generate annual sales of over €10 billion by 2030, driven by recently launched products like Altuviiio (for hemophilia A), Sarclisa (for multiple myeloma) and Tzield (for ...

Also Read: FDA Approves Regeneron/Sanofi’s Blockbuster Dupixent For Smoker’s Lung Disease New pharma launches increased 67.1% to 727 million euros, led by Altuviiio (hemophilia drug ...

The strategic portfolio includes Sobi's medicines Altuvoct, Aspaveli/Empaveli, Doptelet, Gamifant®, Vonjo® and Zynlonta®, and royalty on Sanofi's sales of Altuviiio® and Beyfortus. The ...